Literature DB >> 6474351

Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts.

T R Kohler, J L Kaufman, G Kacoyanis, A Clowes, M C Donaldson, E Kelly, J Skillman, N P Couch, A D Whittemore, J A Mannick.   

Abstract

Recent clinical studies indicate that the use of aspirin and dipyridamole improves graft patency rates in patients with infrainguinal polytetrafluoroethylene (PTFE) grafts and aortocoronary vein grafts. We undertook a prospective, double-blind, randomized study to determine whether these drugs administered postoperatively to patients with PTFE or autologous vein infrainguinal bypasses would improve graft patency during the first 24 months after operation. Patients received either aspirin 325 mg and dipyridamole 75 mg or identical placebo tablets three times a day, taken orally. Patency rates were compared by computing standard life tables and comparing cumulative patency rates. One hundred patients with 102 grafts were studied. The cumulative patency rate at 24 months was not significantly different for the treatment (57%) versus control (67%) groups or for any subgroup. We conclude that aspirin and dipyridamole administered postoperatively in the doses used in this study do not improve the overall patency rates of vein or PTFE infrainguinal bypass grafts.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6474351

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  19 in total

1.  Graft material and results of platelet inhibitor trials in peripheral arterial reconstructions: reappraisal of results from a meta-analysis.

Authors:  H R Watson; A M Skene; G Belcher
Journal:  Br J Clin Pharmacol       Date:  2000-05       Impact factor: 4.335

2.  Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Pablo Alonso-Coello; Sergi Bellmunt; Catherine McGorrian; Sonia S Anand; Randolph Guzman; Michael H Criqui; Elie A Akl; Per Olav Vandvik; Maarten G Lansberg; Gordon H Guyatt; Frederick A Spencer
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 3.  Indications of combined vitamin K antagonists and aspirin therapy.

Authors:  A Loualidi; S H J Bredie; M C H Janssen
Journal:  J Thromb Thrombolysis       Date:  2008-05-31       Impact factor: 2.300

4.  Prophylactic antiplatelet therapy in peripheral arterial disease.

Authors:  R Verhaeghe
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 5.  Factors contributing to success and failure of femorotibial bypass grafts.

Authors:  D F Courtney; W R Flinn; W J McCarthy; J S Yao; J J Bergan
Journal:  World J Surg       Date:  1988-12       Impact factor: 3.352

Review 6.  Do we still need dipyridamole?

Authors:  C R Gibbs; G Y Lip
Journal:  Br J Clin Pharmacol       Date:  1998-04       Impact factor: 4.335

Review 7.  Current concepts of vascular occlusive disease. The significance of endothelial trauma and smooth muscle cell proliferation.

Authors:  M K O'Malley
Journal:  Ir J Med Sci       Date:  1988-03       Impact factor: 1.568

8.  Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

Authors: 
Journal:  BMJ       Date:  1994-01-08

Review 9.  Vein graft failure: from pathophysiology to clinical outcomes.

Authors:  Margreet R de Vries; Karin H Simons; J Wouter Jukema; Jerry Braun; Paul H A Quax
Journal:  Nat Rev Cardiol       Date:  2016-05-19       Impact factor: 32.419

10.  The effect of platelet inhibitory therapy on graft thromboresistance.

Authors:  P E Bearn; H Bull; A M Seddon; A Marston; C N McCollum
Journal:  Int J Exp Pathol       Date:  1993-10       Impact factor: 1.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.